Table 2

Serious infections in patients on bDMARDs, comparison between different bDMARDs (observational studies)

Embedded Image
  • Estimates in bold reflect a risk/ratio statistically significantly different from 1, ie association is statistically significant.

  • More details are found in online supplementary tables S1–S31.

  • *Unadjusted estimate; no adjusted estimate reported.

  • †No upper border of CI given.

  • ‡Non-viral opportunistic infections included fungal infections, tuberculosis, pneumocystosis, nocardiosis/actinomycosis, non-tuberculous mycobacteria, salmonellosis, listeriosis and legionellosis.

  • ABA, abatacept; ADA, adalimumab; aHR, adjusted adjusted Hazard Ratio; CORRONA, Consortium of Rheumatology Researchers of North America; CZP, certolizumab pegol; ETA, etanercept; GOL, golimumab; IFX, infliximab; REAL, Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety; RTX, rituximab; TCZ, tocilizumab; TNFi, tumour necrosis factor α inhibitor.